Korea Exchange · Healthcare
Hana Pharm stock from India: price, numbers and tax
Hana Pharm (293480) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Hana Pharm at a glance
- Price
- ₩8,470.00-₩10.00 (0.12%)
- Market cap
- ₩150.11B
- Day range
- ₩8,370.00 – ₩8,580.00
- P/E
- 8.62
- Dividend yield
- 3.07%
- Volume
- 12.04K
- 1 month
- +0.12%
- 6 months
- -8.23%
- YTD
- -24.51%
- 1 year
- -28.88%
- 5 years
- -58.78%
Hana Pharm statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩239.5B | ₩225.3B | ₩224.5B | ₩210.8B | ₩196.4B |
| Gross profit | ₩146.4B | ₩141.3B | ₩139.6B | ₩131.2B | ₩130.8B |
| Operating income | ₩25.9B | ₩25.2B | ₩27.0B | ₩31.2B | ₩36.0B |
| Net income | ₩8.8B | ₩21.3B | ₩22.3B | ₩24.3B | ₩28.0B |
| Earnings per share | ₩507.00 | ₩1,230.41 | ₩1,291.00 | ₩1,405.08 | ₩1,679.05 |
| EBITDA | ₩37.0B | ₩32.9B | ₩34.7B | ₩37.8B | ₩41.7B |
| Total assets | ₩418.1B | ₩382.0B | ₩348.4B | ₩346.0B | ₩303.5B |
| Total debt | ₩58.7B | ₩29.1B | ₩26.5B | ₩34.1B | ₩10.8B |
| Cash and short-term investments | ₩13.5B | ₩12.2B | ₩6.2B | ₩17.6B | ₩56.9B |
| Shareholders' equity | ₩313.4B | ₩309.2B | ₩278.0B | ₩268.4B | ₩251.9B |
| Operating cash flow | ₩9.2B | ₩25.3B | ₩18.4B | ₩30.9B | ₩25.7B |
| Free cash flow | −₩19.9B | ₩12.1B | ₩3.7B | −₩4.9B | −₩9.2B |
| Capital expenditure | −₩29.0B | −₩13.2B | −₩14.7B | −₩35.8B | −₩34.8B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| REYON Pharmaceutical | 102460.KS | ₩10,280.00 | ₩188.55B |
| Whan In Pharm | 016580.KS | ₩10,180.00 | ₩188.17B |
| Samil Pharmaceutical | 000520.KS | ₩8,350.00 | ₩178.44B |
| JW Lifescience | 234080.KS | ₩10,940.00 | ₩169.40B |
| Ilsung Is | 003120.KS | ₩22,350.00 | ₩160.07B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
| Jeil Pharmaceutical | 271980.KS | ₩10,050.00 | ₩147.78B |
| Ilyang Pharmaceutical | 007570.KS | ₩7,950.00 | ₩142.50B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Hana Pharm from India
What Hana Pharm does
Hana Pharm Co., Ltd. is a pharmaceutical enterprise that manufactures and supplies a diverse range of medicinal goods to both domestic South Korean and international markets. Its comprehensive product line covers various therapeutic categories, such as anesthetics, potent narcotic pain relievers, anti-nausea agents, muscle relaxants, and treatments targeting the cardiovascular, endocrine, gastrointestinal, respiratory, and central nervous systems. Hana Pharm operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Hana Pharm shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.